Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001

Kresken, Michael; Hafner, Dieter; Schmitz, Franz-Josef; Wichelhaus, Thomas A; on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy,

doi:10.1016/j.ijantimicag.2003.11.007

« Previous Next »International Journal of Antimicrobial Agents
Volume 23, Issue 6 , Pages 577-581, June 2004

Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001☆

Michael Kresken
- Antiinfectives Intelligence GmbH, Immenburgstraße 20, 53121 Bonn, Germany
- Corresponding author. Tel.: +49-228-444-7060; fax: +49-228-444-70616.
Dieter Hafner
- Institut für Pharmakologie und klinische Pharmakologie, Heinrich-Heine-Universität, Moorenstraße 5, 40225 Düsseldorf, Germany
- Tel.: +49-211-811-2449; fax: +49-211-811-4781.
Franz-Josef Schmitz
- Institut für Laboratoriumsmedizin, Mikrobiologie, Hygiene und Transfusionsmedizin, Kliniken im Mühlenkreis, Klinikum Minden, Friedrichstraße 17, 32427 Minden, Germany
- Tel.: +49-571-801-3031; fax: +49-571-801-3034.
Thomas A Wichelhaus
- Institut für Medizinische Mikrobiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Paul-Ehrlich-Straße 40, 60596 Frankfurt/Main, Germany
- Tel.: +49-69-6301-6438; fax: +49-69-6301-5767.
on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy

Received 10 October 2003; accepted 28 November 2003.

Abstract

A multicentre surveillance study comprising 26 laboratories located in Austria, Germany, and Switzerland was carried out in November 2001. A total of 787 isolates of Staphylococcus aureus and 456 isolates of Staphylococcus epidermidis mainly recovered from hospitalised patients, were tested. MICs for mupirocin were determined using the broth microdilution procedure. Breakpoints were ≤4mg/l (susceptible), 8–256mg/l (low-level resistance) and ≥512mg/l (high-level resistance). Rates of low- and high-level resistances were 2.9 and 0.9% in S. aureus, and 9.4 and 3.3% in S. epidermidis, respectively. Mupirocin resistance was almost exclusively observed in oxacillin-resistant isolates of S. aureus (MRSA) and S. epidermidis (MRSE). High-level mupirocin resistance was detected in 3.1 and 4.5% of MRSA and MRSE, respectively.